The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epstein, F. H., Levin, E. R., Gardner, D. G., & Samson, W. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390507 · Cited by 1,927
Sch�ller, J., Cassidy, J., Dumont, E., Roos, B., Banken, L., Mori, K., Reigner, B., Utoh, M., Weidekamm, E., & Durston, S. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050043 · Cited by 534
Clinical Pharmacokinetics of Capecitabine
Reigner, B., Blesch, K., & Weidekamm, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140020-00002 · Cited by 388
Stein, B. C., & Levin, R. I. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70054-7 · Cited by 260
Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies
El-Awady, E.-S. E., Moustafa, Y. M., Abo-Elmatty, D. M., & Radwan, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.085 · Cited by 260
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
Jensen, S. A., & Sørensen, J. B. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0178-1 · Cited by 232
Milunski, M. R., Mohr, G. A., Pérez, J. E., Vered, Z., Wear, K. A., Gessler, C. J., Sobel, B. E., Miller, J. G., & Wickline, S. A. (1989) · Circulation · doi:10.1161/01.cir.80.3.491 · Cited by 191
Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.
Rezkalla, S., Kloner, R. A., Ensley, J., al-Sarraf, M., Revels, S., Olivenstein, A., Bhasin, S., Kerpel-Fronious, S., & Turi, Z. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.509 · Cited by 187
Cardiotoxicity of the Antiproliferative Compound Fluorouracil
Becker, K., Erckenbrecht, J. F., aussinger, D. H., & Frieling, T. (1999) · Drugs · doi:10.2165/00003495-199957040-00003 · Cited by 172
5-Fluorouracil induces arterial vasocontractions
Südhoff, T., Enderle, M.-D., Pahlke, M., Petz, C., Teschendorf, C., Graeven, U., & Schmiegel, W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh150 · Cited by 168
Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil
Meyer, C. C., Calis, K. A., Burke, L. B., Walawander, C. A., & Grasela, T. H. (1997) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03748.x · Cited by 162
5-Fluorouracil cardiotoxicity.
Lomeo, A. M., Avolio, C., Iacobellis, G., et al. (1990) · PubMed · Cited by 155
Cutsem, E. V., Hoff, P. M., Blum, J., Abt, M., & Osterwalder, B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf108 · Cited by 149
Electrocardiographic predictors of atrial fibrillation
Perez, M. V., Dewey, F. E., Marcus, R. R., Ashley, E. A., Al‐Ahmad, A., Wang, P. J., & Froelicher, V. F. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.08.002 · Cited by 134
The Prodrugs of 5-Fluorouracil
Malet‐Martino, M., Jolimaître, P., & Martino, R. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354146 · Cited by 128
Ma, H., Jones, K. R., Guo, R., Xu, P., Shen, Y., & Ren, J. T. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05323.x · Cited by 111
Clinical Cardiotoxicity of 5‐Fluorouracil
Keefe, D. L., Roistacher, N., & Pierri, M. K. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb01943.x · Cited by 104
High Incidence of Angina pectoris in Patients Treated with 5-Fluorouracil
Wacker, A., Lersch, C., Scherpinski, U., Reindl, L., & Seyfarth, M. (2003) · Oncology · doi:10.1159/000072334 · Cited by 103
Jensen, S. A., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1669-x · Cited by 86
Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure.
Balion, C. M., Santaguida, P. L., Hill, S., Worster, A., McQueen, M., Oremus, M., McKelvie, R. S., Booker, L., Fagbemi, J., Reichert, S. M., et al. (2006) · PubMed · Cited by 71
Yılmaz, U., Öztop, İ., Ciloglu, A., Okan, T., Tekin, Ü. İ., Yaren, A., Somali, I., Alacacıoğlu, A., & Kırımlı, Ö. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01323.x · Cited by 48
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
American Cancer Society Colorectal Cancer Survivorship Care Guidelines
El‐Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt‐Chapman, M. L., Cannady, R. S., Wong, S. L., Rose, J., Barbour, A. L., et al. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21286 · Cited by 475
5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433
Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue
Herrmann, J., Yang, E. H., Iliescu, C. A., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., Grines, C. L., & Marmagkiolis, K. (2016) · Circulation · doi:10.1161/circulationaha.115.018347 · Cited by 329
Metadata
- Authors
- Polk, A., Vaage-Nilsen, M., Vistisen, K., & Nielsen, D. L.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 39
- Issue
- 8
- Pages
- 974-984
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2136571540
- Cited by
- 329
- References
- 21
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.